OxidoResist
Identification and validation of complementary therapies to
overcome resistance to a novel anticancer compound inducing
oxidative stress in cancer cells.
As a Eurostars project, OxidoResist is an international, SME-driven project for innovative product development with a fast track to market.
The OxidoResist project aims to develop a technology to overcome anticancer drug resistance. The OxidoResist technology will apply innovative single cell proteomics and modern AI-based bioinformatics to identify FDA-approved drug(s) that will overcome resistance and have a synergistic effect in combination with a given anti-cancer drug.
We will develop a universal pipeline (joining wet lab, AI-based bioinformatics, cheminformatics and network modeling approaches) for the discovery of optimal complementary drug combinations to fight the resistance to target-specific therapeutic agents. The developed pipeline will be applied to a new highly effective target-specific anticancer compound that was developed in the EuroStars project OxidoCurin (2017-2020).
Further information
The OxidoResist project aims to develop a technology to overcome drug resistance in cancer. The OxidoResist technology will apply the innovative single-cell proteomics and modern AI-based bioinformatics to discover which FDA-approved drugs will overcome resistance when combined with the anticancer drug under study. We will develop a universal pipeline for the discovery of optimal drug combinations that overcome resistance to target-specific therapies.
The project aims to develop and introduce two new products on the market:
1) Medicines against cancer with a new mechanism of action
2) Service platform
The project aims to develop a technology to overcome anticancer drug resistance. The technology will apply the innovative single cell proteomics and modern AI-based bioinformatics to discover which FDA-approved drugs will overcome resistance in combination with anti-cancer drugs under study. We will develop a universal pipeline (joining top labs, AI-based bioinformatics, chemoinformatics, and network modeling) for the discovery of optimal drug combinations that overcome resistance to target-specific therapies.
Contract period
January 2023 – December 2024
Coordinator
The project is coordinated by Dr. Alexander Kel, geneXplain GmbH, Wolfenbüttel, Germany
Partners
Karolinska Institute, Prof. Dr. R. Zubarev and Prof. Dr. G. Selivanova
HDXperts AB
Medizinische Hochschule Hannover, Prof. Dr. J. Borlak